CY1121335T1 - Anti-cxcr3 αντισωματα - Google Patents
Anti-cxcr3 αντισωματαInfo
- Publication number
- CY1121335T1 CY1121335T1 CY20181101236T CY181101236T CY1121335T1 CY 1121335 T1 CY1121335 T1 CY 1121335T1 CY 20181101236 T CY20181101236 T CY 20181101236T CY 181101236 T CY181101236 T CY 181101236T CY 1121335 T1 CY1121335 T1 CY 1121335T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cxcr3
- antibodies
- cxcr3 antibodies
- diagnosis
- occurring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261588936P | 2012-01-20 | 2012-01-20 | |
| PCT/US2013/022280 WO2013109974A2 (en) | 2012-01-20 | 2013-01-18 | Anti-cxcr3 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121335T1 true CY1121335T1 (el) | 2020-05-29 |
Family
ID=47633576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181101236T CY1121335T1 (el) | 2012-01-20 | 2018-11-22 | Anti-cxcr3 αντισωματα |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US8865870B2 (enExample) |
| EP (1) | EP2804878B1 (enExample) |
| JP (3) | JP6352812B6 (enExample) |
| KR (2) | KR20200014441A (enExample) |
| CN (1) | CN104507967B (enExample) |
| AR (1) | AR090056A1 (enExample) |
| AU (1) | AU2013209492B2 (enExample) |
| BR (1) | BR112014017814A8 (enExample) |
| CA (1) | CA2862222A1 (enExample) |
| CY (1) | CY1121335T1 (enExample) |
| DK (1) | DK2804878T3 (enExample) |
| ES (1) | ES2698606T3 (enExample) |
| HR (1) | HRP20181874T1 (enExample) |
| HU (1) | HUE041900T2 (enExample) |
| IL (2) | IL233694A0 (enExample) |
| LT (1) | LT2804878T (enExample) |
| MX (1) | MX359854B (enExample) |
| PL (1) | PL2804878T3 (enExample) |
| PT (1) | PT2804878T (enExample) |
| RS (1) | RS58141B1 (enExample) |
| RU (1) | RU2663141C2 (enExample) |
| SG (2) | SG11201406762QA (enExample) |
| SI (1) | SI2804878T1 (enExample) |
| TW (1) | TWI596112B (enExample) |
| UY (1) | UY34582A (enExample) |
| WO (1) | WO2013109974A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| EA201790437A1 (ru) | 2014-08-22 | 2017-08-31 | Сорренто Терапьютикс, Инк. | Антигенсвязывающие белки, связывающиеся с cxcr3 |
| CA3003458A1 (en) | 2015-10-29 | 2017-05-04 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
| EP3464349A4 (en) * | 2016-05-23 | 2020-08-26 | New York University | COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS |
| TW201837053A (zh) * | 2016-12-22 | 2018-10-16 | 法商賽諾菲公司 | 具有消耗活性的人源化cxcr3抗體及其使用方法 |
| EP3559036A1 (en) * | 2016-12-22 | 2019-10-30 | Sanofi | Anti-human cxcr3 antibodies for treatment of vitiligo |
| US20180244787A1 (en) | 2016-12-22 | 2018-08-30 | Sanofi | Anti-human cxcr3 antibodies for treatment of vitiligo |
| JP7384811B2 (ja) * | 2018-02-16 | 2023-11-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 白斑を処置するための方法及び組成物 |
| KR102074798B1 (ko) * | 2018-06-15 | 2020-02-07 | 코아스템(주) | 자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도 |
| JP2022507295A (ja) * | 2018-11-14 | 2022-01-18 | アーチ オンコロジー，インコーポレイテッド | 治療用ＳＩＲＰα抗体 |
| BR112022017048A2 (pt) | 2020-02-26 | 2022-11-16 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos para usar os mesmos |
| BR112022021992A2 (pt) * | 2020-04-30 | 2023-01-03 | Arch Oncology Inc | Método de tratamento de câncer em um sujeito em necessidade do mesmo |
| EP4288455A1 (en) | 2021-02-03 | 2023-12-13 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| US20250277026A1 (en) * | 2021-03-02 | 2025-09-04 | Novarock Biotherapeutics, Ltd. | Antibodies against claudin-6 and uses thereof |
| CN118103070A (zh) * | 2021-08-09 | 2024-05-28 | 默克专利有限公司 | 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250381184A1 (en) | 2022-09-09 | 2025-12-18 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist |
| WO2025185738A1 (zh) * | 2024-03-08 | 2025-09-12 | 演生潮(北京)生物科技有限公司 | 靶向cxcr3的抗原结合蛋白及其应用 |
| WO2026069312A1 (en) | 2024-09-24 | 2026-04-02 | Yeda Research And Development Co. Ltd. | Immune cells expressing an inducible therapeutic agent and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US565332A (en) | 1896-08-04 | Toy for making soap-bubbles | ||
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
| JP2826272B2 (ja) | 1993-10-26 | 1998-11-18 | タイガースポリマー株式会社 | 中空樹脂成形品の製造装置及び製造方法 |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| AU734090B2 (en) * | 1996-09-10 | 2001-06-07 | Millennium Pharmaceuticals, Inc. | CXCR3 chemokine receptor, antibodies, nucleic acids, and methods of use |
| US6140064A (en) * | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2001249546A1 (en) * | 2000-03-27 | 2001-10-08 | Corixa Corporation | Methods for treating disease with antibodies to cxcr3 |
| WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| BRPI0411945A (pt) * | 2003-06-30 | 2006-10-24 | Bio Technology General Israel | Anticorpos e seus usos |
| WO2005030793A2 (en) | 2003-09-24 | 2005-04-07 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
| ATE557042T1 (de) * | 2004-03-23 | 2012-05-15 | Lilly Co Eli | Anti-myostatin-antikörper |
| AU2005334481A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| AU2007238034A1 (en) | 2006-04-14 | 2007-10-25 | Trubion Pharmaceuticals Inc. | Binding proteins comprising immunoglobulin hinge and Fc regions having altered Fc effector functions |
| JP5371780B2 (ja) * | 2007-02-01 | 2013-12-18 | テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド | Ｃｘｃｒ３に対するヒト化抗体 |
| MX338397B (es) | 2007-08-29 | 2016-04-15 | Sanofi Aventis | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| WO2010056907A2 (en) | 2008-11-12 | 2010-05-20 | The Scripps Research Institute | Compounds that induce pancreatic beta-cell expansion |
| WO2010103517A1 (en) * | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
| JP5894939B2 (ja) * | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
-
2013
- 2013-01-18 WO PCT/US2013/022280 patent/WO2013109974A2/en not_active Ceased
- 2013-01-18 CN CN201380015401.8A patent/CN104507967B/zh not_active Expired - Fee Related
- 2013-01-18 MX MX2014008728A patent/MX359854B/es active IP Right Grant
- 2013-01-18 HU HUE13702548A patent/HUE041900T2/hu unknown
- 2013-01-18 US US13/745,377 patent/US8865870B2/en not_active Expired - Fee Related
- 2013-01-18 SG SG11201406762QA patent/SG11201406762QA/en unknown
- 2013-01-18 EP EP13702548.2A patent/EP2804878B1/en active Active
- 2013-01-18 HR HRP20181874TT patent/HRP20181874T1/hr unknown
- 2013-01-18 ES ES13702548T patent/ES2698606T3/es active Active
- 2013-01-18 RU RU2014134043A patent/RU2663141C2/ru active
- 2013-01-18 KR KR1020207002561A patent/KR20200014441A/ko not_active Ceased
- 2013-01-18 JP JP2014553482A patent/JP6352812B6/ja not_active Expired - Fee Related
- 2013-01-18 RS RS20181422A patent/RS58141B1/sr unknown
- 2013-01-18 SI SI201331249T patent/SI2804878T1/sl unknown
- 2013-01-18 KR KR1020147023225A patent/KR102073034B1/ko not_active Expired - Fee Related
- 2013-01-18 PL PL13702548T patent/PL2804878T3/pl unknown
- 2013-01-18 BR BR112014017814A patent/BR112014017814A8/pt not_active Application Discontinuation
- 2013-01-18 CA CA2862222A patent/CA2862222A1/en not_active Abandoned
- 2013-01-18 SG SG10201700735PA patent/SG10201700735PA/en unknown
- 2013-01-18 AU AU2013209492A patent/AU2013209492B2/en not_active Ceased
- 2013-01-18 LT LTEP13702548.2T patent/LT2804878T/lt unknown
- 2013-01-18 DK DK13702548.2T patent/DK2804878T3/en active
- 2013-01-18 PT PT13702548T patent/PT2804878T/pt unknown
- 2013-01-21 UY UY0001034582A patent/UY34582A/es not_active Application Discontinuation
- 2013-01-21 TW TW102102282A patent/TWI596112B/zh not_active IP Right Cessation
- 2013-01-21 AR ARP130100184A patent/AR090056A1/es unknown
-
2014
- 2014-07-17 IL IL233694A patent/IL233694A0/en unknown
- 2014-09-08 US US14/480,052 patent/US9765144B2/en not_active Expired - Fee Related
-
2017
- 2017-08-04 US US15/669,556 patent/US20180086838A1/en not_active Abandoned
-
2018
- 2018-05-07 JP JP2018089004A patent/JP6646100B2/ja not_active Expired - Fee Related
- 2018-09-14 US US16/132,333 patent/US20190119391A1/en not_active Abandoned
- 2018-11-22 CY CY20181101236T patent/CY1121335T1/el unknown
-
2019
- 2019-12-24 IL IL271697A patent/IL271697A/en unknown
-
2020
- 2020-01-08 JP JP2020001152A patent/JP2020072715A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121335T1 (el) | Anti-cxcr3 αντισωματα | |
| CY1122278T1 (el) | Αντι il-36r αντισωματα | |
| CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
| CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
| CY1122816T1 (el) | Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1 | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| BR112017003582A2 (pt) | anticorpos, composições e usos | |
| MX384191B (es) | Molecula de union al antigeno especifico para el tejido objetivo. | |
| CO2017002719A2 (es) | Anticuerpos anti-glucagón | |
| EP4302784A3 (en) | Anti-ntb-a antibodies and related compositions and methods | |
| MY177564A (en) | Anti-nr10 antibody and use thereof | |
| EA201691060A1 (ru) | Терапия транстиретинового (ттр) амилоидоза антителами, а также антитела, полученные от человека для указанной терапии | |
| EA201201357A1 (ru) | Антитела к cd40 | |
| BR112014016299A8 (pt) | imunoglobulinas de domínio variável e usos das mesmas | |
| AU2012205878A8 (en) | miRNA for treating diseases and conditions associated with neo-angiogenesis | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| PH12013501490A1 (en) | Methods for diagnosing and treating eye-length related disorders | |
| UA113712C2 (xx) | Антитіло до fap і способи його застосування | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| EA201591191A1 (ru) | Антитела против ntb-a и связанные с ними композиции и способы | |
| EP3988673A3 (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease | |
| EA201492163A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ | |
| BR112014002140A2 (pt) | anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer |